EUFLEXXA®

Product Description

EUFLEXXA® is a sterile, viscoelastic gel containing 1% sodium hyaluronate designed for intra-articular injection into the knee joint. This non-avian sourced hyaluronic acid formulation offers targeted viscosupplementation therapy for patients experiencing symptoms of knee osteoarthritis. 

Each package contains three 2ml pre-filled syringes manufactured by Ferring Pharmaceuticals, offering medical professionals a reliable treatment option for pain management in degenerative joint conditions.

EUFLEXXA® Dosage and Administration

EUFLEXXA therapy requires a series of three joint injections administered at weekly intervals. 

Each EUFLEXXA injection delivers 2ml of sodium hyaluronate solution directly into the affected knee joint using a 17-21 gauge needle. Medical professionals must follow strict aseptic techniques during administration, first removing any joint effusion before delivering the EUFLEXXA syringe contents. 

The complete three-injection course maximizes therapeutic efficacy, with subsequent treatment courses potentially scheduled every six months based on patient response and clinical assessment.

Ingredient Information

The EUFLEXXA formulation contains sodium hyaluronate at a concentration of 10mg/mL as the primary active ingredient. Supporting components include sodium chloride (8.5mg/ml), disodium hydrogen phosphate dodecahydrate (0.56mg/ml), sodium dihydrogen phosphate dihydrate (0.05mg/ml), and water for injection. 

The hyaluronic acid component is produced through biofermentation, ensuring high purity and consistency in molecular weight. This phosphate-buffered saline system maintains optimal pH and osmolarity for intra-articular administration, thereby supporting the stability and biocompatibility of hyaluronate within the joint environment.

Storage Instructions

EUFLEXXA® requires refrigerated storage at 2-8°C in a dark environment without freezing. The product should be removed from refrigeration 20-30 minutes before administration to reach room temperature (15-25°C). Once at room temperature, EUFLEXXA® may be stored for up to six months under appropriate conditions. Medical facilities should implement proper inventory management to track order dates and ensure product integrity throughout the storage period.

EUFLEXXA® Contraindications

EUFLEXXA® is contraindicated in patients with known hypersensitivity to hyaluronic acid or any formulation components. The product should not be administered to patients with active knee infections or skin diseases affecting the injection site. Medical professionals must avoid EUFLEXXA injections in patients with bleeding disorders or those receiving anticoagulant therapy that significantly increases hemorrhage risk. Pregnancy and lactation represent relative contraindications that require careful risk-benefit assessment before initiating treatment.

EUFLEXXA® Precautions and Warnings

Healthcare providers must exercise appropriate caution when administering EUFLEXXA® injections:

• Use strict aseptic technique during injection procedures
• Patients should avoid strenuous activities for 48 hours post-injection
• Monitor for signs of joint infection following treatment
• Inspect syringes for particulate matter or discoloration before use

EUFLEXXA® Manufacturer and Regulatory Information

Ferring Pharmaceuticals manufactures EUFLEXXA® under strict pharmaceutical quality standards and regulatory oversight. The product maintains FDA approval for the treatment of knee osteoarthritis in eligible patients. Healthcare professionals can order EUFLEXXA through authorized medical supply distributors who ensure product authenticity and proper cold chain management.

For medical professionals seeking to buy EUFLEXXA online, authorized distributors offer secure ordering platforms with guaranteed product authenticity and proper storage throughout the supply chain. Healthcare providers can order EUFLEXXA online through established medical supply networks that specialize in orthopedic injection products.